Weight Loss Is Only Part of the Story
Ozempic. Wegovy. Mounjaro. Zepbound.
Few medical treatments have transformed the conversation around obesity as quickly as GLP-1 and related incretin medicines.
And there is no point pretending they don't work.
For appropriately selected patients, medicines such as semaglutide and tirzepatide can produce substantial weight loss. They can also improve important metabolic outcomes, and GLP-1-based therapies have become legitimate medical tools in the treatment of obesity and type 2 diabetes.
But a successful health strategy should be judged by more than one number on the bathroom scales.
We should also be asking:
What kind of weight are we losing?
What happens when the medication stops?
What happens to muscle?
What has the person actually learned about food?
What are the risks?
And perhaps most importantly: are we creating better health—or simply creating another form of long-term treatment?
These questions deserve serious discussion.
1. The Weight Can Come Back
This is perhaps the most important part of the GLP-1 story.
In the STEP 1 extension study involving semaglutide, participants regained approximately two-thirds of their prior weight loss during the year after treatment and lifestyle intervention were withdrawn.
The tirzepatide story is similarly revealing.
In the SURMOUNT-4 randomized trial, participants initially lost an average 20.9% of their body weight during 36 weeks of tirzepatide treatment.
Those who continued treatment subsequently lost another 5.5%.
But those switched to placebo regained about 14% of their body weight during the following 52 weeks.
That doesn't mean the medicines failed.
It tells us something much more important:
For many people, the medication manages the biological drivers of obesity while they are taking it. It does not necessarily eliminate those drivers.
That distinction should be explained before treatment begins.
2. Are We Treating Obesity—or Managing It Indefinitely?
The World Health Organization now describes obesity as a chronic, relapsing disease and conditionally recommends GLP-1 therapies as part of comprehensive obesity treatment.
Importantly, WHO does not present an injection as a substitute for lifestyle.
Its recommendations specifically place these medicines alongside healthy nutrition, physical activity and professional support.
That distinction matters.
There is an enormous difference between:
using medication as one tool within a comprehensive health strategy
and
allowing medication to become the entire strategy.
If appetite returns strongly when treatment ends and substantial weight regain follows, the patient deserves to understand that possibility from the beginning.
A prescription should ideally come with an entry strategy, a nutritional strategy, a muscle-preservation strategy and, where appropriate, a carefully supervised long-term or transition strategy.
3. The Muscle Question Cannot Be Ignored
The scales cannot distinguish between fat, water and lean tissue.
That matters enormously.
A 2026 systematic review and meta-analysis examining GLP-1 receptor agonists at obesity-management doses found reductions in absolute lean mass. The authors nevertheless concluded that lean-mass loss should not be regarded as a reason to avoid these effective medicines.
Instead, they emphasised something extremely important:
nutrition and physical exercise need to accompany treatment to preserve or improve muscle.
This should become central to the GLP-1 conversation—particularly for older adults.
Muscle isn't cosmetic.
It contributes to:
· strength
· mobility
· balance
· metabolic health
· glucose disposal
· independence
· healthy ageing.
Therefore the goal should never simply be:
LOSE WEIGHT.
It should be:
LOSE EXCESS FAT WHILE PROTECTING MUSCLE AND FUNCTION.
A smaller body is not automatically a healthier body.
4. The Gastrointestinal Price
The most familiar adverse effects of GLP-1 therapies are gastrointestinal.
Nausea, vomiting, diarrhoea, constipation and abdominal symptoms are well recognised.
For many people these effects are manageable and may improve over time.
For others they can become significant enough to affect eating, hydration, quality of life or continuation of treatment.
And there are less common but more serious complications that patients need to understand.
GLP-1 medicines have been associated with gallbladder and biliary disease.
A systematic review and meta-analysis involving 76 randomized clinical trials and more than 103,000 participants found GLP-1 receptor agonist treatment was associated with an increased risk of gallbladder or biliary disease.
The association was particularly pronounced in trials where the drugs were being used for weight loss.
Again, perspective matters.
This does not mean everyone taking a GLP-1 medicine will develop gallstones.
It means that genuine medical treatment requires genuine informed consent.
5. Even Rare Risks Matter When Millions Are Treated
In 2025, the European Medicines Agency's safety committee concluded that non-arteritic anterior ischaemic optic neuropathy—NAION—should be listed as a very rare side effect of semaglutide medicines.
NAION can cause loss of vision.
EMA estimated the frequency as up to approximately one case per 10,000 people taking semaglutide and advised people experiencing sudden loss of vision or rapidly worsening eyesight to seek medical attention.
This risk is rare.
But that's exactly why balanced health communication matters.
We should neither exaggerate rare complications to frighten people nor hide them because they complicate the marketing story.
6. The Compounding and Online-Peptide Wild West Is Another Problem
The popularity of GLP-1 medicines has spawned another industry: compounded, copycat and unapproved products sold through various channels.
This is not the same discussion as appropriately prescribed, regulator-approved medication.
The US FDA has specifically warned about unapproved compounded semaglutide and tirzepatide products.
As of May 31, 2026, FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
FDA also warns that adverse events involving some compounded products may be underreported and has previously highlighted dosing errors resulting in severe nausea, vomiting and hypoglycaemia.
There is an important lesson here:
Popularity creates opportunity—but it also creates opportunists.
People should not be buying mystery peptides from questionable internet sources because they want faster or cheaper weight loss.
7. Medication Can Reduce Hunger. But Can It Teach You How to Live?
This is where the discussion becomes bigger than pharmacology.
A medicine can reduce appetite.
It can increase satiety.
It can make eating less considerably easier.
Those effects can be extraordinarily useful.
But an injection cannot shop for your groceries.
It cannot teach your children what a healthy meal looks like.
It cannot explain protein quality.
It cannot teach you to cook.
It cannot lift weights for you.
It cannot rebuild muscle.
It cannot restructure your food environment.
It cannot teach you how to manage emotional eating.
And it cannot automatically create the habits required for decades of healthy living.
Those things still belong to us.
That is not an argument against medicine.
It is an argument against medicine without education.
8. Perhaps We Are Asking the Wrong Question
For decades we have asked:
"How do we make people lose weight?"
Perhaps the better question is:
"How do we help people become healthier for the rest of their lives?"
Those are not necessarily the same objective.
Weight loss can be part of improved health.
But sustainable health also involves nutrition, muscle, movement, sleep, metabolic health, relationships with food, confidence and the ability to make informed choices.
This is where lifestyle medicine must reclaim its rightful place.
9. Food Is Not the Enemy
One unfortunate consequence of the weight-loss industry has been the idea that hunger itself is something that simply needs to be switched off.
Human appetite is far more complex.
Our gastrointestinal tract produces its own satiety signals, including naturally occurring GLP-1, in response to food and digestion.
Protein, dietary fibre, minimally processed foods and appropriate meal composition can all contribute to satiety through multiple physiological mechanisms.
That doesn't mean broccoli produces the pharmacological effect of semaglutide.
It doesn't.
And lifestyle treatment should not be dishonestly presented as chemically equivalent to a GLP-1 drug.
But it does mean the human body possesses sophisticated appetite-regulation systems that good nutrition can work with rather than ignore.
That should be empowering.
10. There Should Be an "Off-Ramp" Conversation
Not everyone taking GLP-1 therapy should stop.
For some patients, long-term pharmacotherapy may be appropriate and medically beneficial.
But people who want eventually to discontinue treatment deserve more than:
"Good luck—eat less and exercise."
They need a strategy.
That strategy may include:
adequate protein, resistance exercise, whole-food nutrition, meal planning, monitoring, behavioural support, sleep, education, accountability and ongoing professional supervision.
And because substantial regain can occur after discontinuation, stopping prescribed GLP-1 medication should be discussed with the treating clinician rather than attempted abruptly or independently.
The objective should be to build as much capability as possible while the medication is working.
THE NEXT REVOLUTION SHOULD BE SELF-EMPOWERMENT
The first revolution was pharmacological.
Perhaps the next one should be educational.
Imagine a healthcare system where somebody receiving a GLP-1 prescription was simultaneously taught:
how to eat well,
how to preserve muscle,
how to shop and cook,
how to exercise,
how to recognise hunger and satiety,
how to manage setbacks,
and how to build a lifestyle capable of lasting decades.
Then medication isn't necessarily the enemy.
It becomes one possible tool.
And the patient remains at the centre.
That is the distinction we desperately need.
Don't Just Lose Weight. Learn How to Live Well.
The future of obesity management should not become a battle between drugs versus diet.
That is far too simplistic.
The real debate should be about what produces the greatest long-term health, strength, independence and quality of life for each individual.
For some people that will include medication.
For some it may not.
For others, medication may provide the opportunity to finally establish the nutrition and lifestyle practices they have struggled to achieve previously.
But regardless of which pathway someone chooses, one principle should remain:
Never outsource your entire health to an injection.
Use medical science where appropriate.
Use good nutrition.
Build muscle.
Move your body.
Understand your food.
Learn about your metabolism.
Work with qualified health professionals.
And become an active participant in your own health rather than merely the recipient of another treatment.
Because ultimately the most valuable outcome isn't simply losing kilograms.
It is gaining health, knowledge, strength and the confidence to look after yourself for life.
Evidence & Further Reading
World Health Organization (2025). WHO guideline on GLP-1 therapies for the treatment of obesity in adults. WHO conditionally recommends these therapies as part of comprehensive treatment incorporating healthy diet, physical activity and professional support.
Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA;331(1):38–48.
Wilding JPH et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism.
He L et al. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine.
2026 systematic review/meta-analysis. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health. The analysis reinforces the importance of nutritional and exercise interventions during treatment.
European Medicines Agency (2025). PRAC concluded that NAION should be classified as a very rare adverse effect of semaglutide medicines.
US Food and Drug Administration (updated 2026). FDA concerns regarding unapproved and compounded GLP-1 products used for weight loss.
Important note
This article is for education and discussion, not individual medical advice. GLP-1 and GIP/GLP-1 medicines have proven benefits and can be appropriate treatments for obesity, diabetes and associated conditions. Anyone taking prescribed medication should discuss changes or discontinuation with their treating healthcare professional.